Otsuka (OTCMKTS:OTSKY) Stock Bumped Down to Hold by Zacks Research

Zacks Research downgraded shares of Otsuka (OTCMKTS:OTSKY) from a strong-buy rating to a hold rating in a research note issued to investors on Monday morning,Zacks reports.

Otsuka Stock Performance

OTCMKTS OTSKY opened at $37.68 on Monday. The company’s 50 day moving average is $37.29 and its 200-day moving average is $35.15. Otsuka has a 12-month low of $26.11 and a 12-month high of $40.92. The company has a quick ratio of 1.65, a current ratio of 2.21 and a debt-to-equity ratio of 0.05. The firm has a market cap of $40.48 billion, a P/E ratio of 16.17, a price-to-earnings-growth ratio of 2.75 and a beta of 0.08.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings results on Friday, October 30th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The company had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.42 billion. Otsuka had a net margin of 14.36% and a return on equity of 11.90%. Sell-side analysts predict that Otsuka will post 2.21 earnings per share for the current year.

Otsuka Company Profile

Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.